Stavros Selemidis

Professor Stavros Selemidis

Professor

Black background. Multiple coloured clouds in the foreground. Colours range from white, pink, green, and blue.
Stavros Selemidis profile photo, he is wearing a suit and smiling

Contact details

STEMHealth and Biomedical Sciences


Emailstavros.selemidis@rmit.edu.au


Phone: +61 399257182


Campus: Bundoora


Programs

 BIOL2145 - Cardiorespiratory Biology


 BHO58 - Bachelor of Health and Biomedical Sciences (Honours)


 ONSP2494 - Pharmacology and Therapeutics 


 ONSP2563 - Applied Pharmacology


More information

Stavros Selemidis profile photo, he is wearing a suit and smiling

Contact details

STEMHealth and Biomedical Sciences


Emailstavros.selemidis@rmit.edu.au


Phone: +61 399257182


Campus: Bundoora


Programs

 BIOL2145 - Cardiorespiratory Biology


 BHO58 - Bachelor of Health and Biomedical Sciences (Honours)


 ONSP2494 - Pharmacology and Therapeutics 


 ONSP2563 - Applied Pharmacology


More information

Stavros is a pharmacologist and the head of the Oxidant and Inflammation Biology Group (OXIB) in the SHBS at RMIT University and the Chief Scientist of the Biotech Company ViraLok Therapeutics Pty Ltd.

Overview

Professor Stavros Selemidis is a pharmacologist and the head of the Oxidant and Inflammation Biology Group (OXIB) in the STEM College and School of Health and Biomedical Sciences (SHBS) at RMIT University. Stavros is also the CSO of the Biotech Company ViraLok Therapeutics Pty Ltd that he founded at RMIT. Stavros is internationally and nationally recognized for his fundamental and clinically translational research which aims to unravel novel disease paradigms and therapeutic targets for respiratory viruses including influenza (IAV), common cold and COVID-19 in humans and livestock industries. To achieve this Stavros has assembled and leads a multi-disciplinary, multi-cultural and gender balanced research team of postdocs, research assistants, HDRs, Honours and WiLstudents at RMIT. Stavros is an integral leader of a large international research program consisting of a consortium of researchers and clinicians that investigate viral and cancer disease mechanisms with a developmental pipeline for therapeutic development and commercialization. His research program is a 3 pillar strategy entailing: Fundamental Biology; Pharmacology and Drug discovery and Pre-clinical Translational Biology all 3 of which are channeling novel IP intoViraLok Therapeutics, which is the entity for translational and commercialization outcomes.

Stavros has >65 peer reviewed publications in some of the highest impact international journals (ave impact factor 8.72; >94% Q1) including Nature Reviews Drug Discovery, Nature Communications, Molecular Cancer, Gastroenterology and PNAS. He has a H-index of 32 with >4,100 citations, and a significant number of these publications are linked to his HDR supervision. Stavros has held prestigious and highly competitive National based fellowships from the National Health and Medical Research Council of Australia (NHMRC) and Australian Research Council (ARC). Stavros' prestigious research fellowships served as a strong foundation for garnering a continuous stream of competitive Category 1 and 3 funding including a total of ~$15 Mill as a chief/partner investigator, of which ~$6M obtained as the lead investigator. Since being recruited to RMIT at the beginning of 2017, Stavros has led an international consortium of commercially funded work that has confidentiality/patent agreements and licensing agreements, which facilitated the advent of ViraLok Therapeutics Pty Ltd. As the CSO of ViraLok Therapeutics, Stavros is the lead investigator of all pre-clinical studies including an international COVID-19 pre-clinical trial and the lead scientist for current and future Big Pharmaceutical company engagement.

Stavros' international reputation as a respiratory and cardiovascular pharmacologist led to sustained and ongoing senior contributions to National government agencies including NHMRC, consisting of NHMRC Grant Review and Fellowship Panels and as an expert peer reviewer of international grant proposals. Stavros has served on international society committees, and is currently a Deputy editor of the leading Australasian Respiratory Disease Journal, Respirology.

Stavros has been invited to present at prestigious Gordon Research conferences, and to >50 local and international conferences and institutions, including in clinically relevant Hospital Grand Round seminar series in major national hospitals. Stavros has graduated multiple HDR students who have undertaken post-doctoral positions in exclusive universities including King’s College London, Harvard University and University of California and who have built careers in academia and industry. Stavros actively contributes to internal RMIT based committees including being a member of the RMIT animal ethics committee as well as the SEH/STEM college OHS committee.

Web

Industry experience

2021 - Service agreement with Viroclinics (Netherlands)

2020 - Advent of ViraLoK Therapeutics Pty Ltd.

2020 - Chief Scientist of ViraLoK Therapeutics Pty Ltd.

2014 - ongoing- Collaborator with Envision Sciences Pty Ltd.

Web

Research

The focus of the research of the Oxidant and Inflammation Biology (OXIB) Group is to identify novel therapeutics for viral diseases and cancer. The research program has 4 major projects and for each project there is a strong integration with collaborators at RMIT (Profs Ross Vlahos and Steven Bozinovski), and both nationally (Prof Doug Brooks; UniSA) and internationally (Prof John O'Leary; Trinity College Dublin).

The first project focusses on the development of novel therapeutics for viruses including influenza, rhinovirus, Dengue virus and COVID-19. With ViraLokTherapeutics we are developing antiviral and anti-inflammatory drugs that thus far have shown good efficacy in pre-clinical models.

The second project of OXIB's ongoing research program is to develop therapeutics for viral diseases in livestock industries. This originated from our highly visible Nature Communications paper that provides evidence of a drug targetable process that underpins viral disease in animals. Pig and poultry industries suffer significantly from viral diseases that are a major animal welfare issue; a global economic burden and a critical source of viral species that ultimately transmit to man and cause global pandemics.

The third project aims to unravel fundamental viral disease mechanisms in athigh risk populations such as pregnant women and cardiovascular patients. Viruses cause more significant disease in these cohorts and our research has thus far identified novel mechanisms of this exacerbated disease and novel therapeutic strategies. Virus infections in pregnancy also lead to significant complications for the offspring, in particular, maternal infection has been associated with neurodevelopmental disorder including schizophrenia. This work is an ongoing collaboration with Monash University (Prof Arthur Christopoulos) and The University of Melbourne (Prof Christos Pantelis).

The fourth project is part of an international research program for cancer and cancer metastasis in collaboration with researchers from UniSA (Prof Doug Brooks) and Trinity College Dublin (Prof John O’Leary). This research program is funded by NHMRC and Industry, in particular, Envision Sciences Pty Ltd. OXIB's role in this major global collaborative network is to provide critical pre-clinical models to test the efficacy of our novel therapeutics against prostate cancer; unravel diagnostic markers and biomarkers of cancer pathogenesis. This line of research and engagement is achieved by an amalgamation, of OXIB’s activities with those of Profs Doug Brooks and John O’Leary and the industry partner Envision Sciences Pty Ltd.

Research keywords

Respiratory Disease, Cardiovascular Disease, Drug Discovery, Pharmacology, Influenza, Common Cold, COVID-19, Virus, Inflammation

Research output summary

65

Publications

17

Projects

8

Awards

Web

Supervisor interest areas

  • Biomedical Research
  • Respiratory Disease
  • Viral Disease
  • Drug Discovery
  • Pharmacology 
  • Infectious Diseases
  • Cancer

Supervisor projects

  • Targeting endosomal NOX2 oxidase in viral disease.
  • Endosomal reactive oxygen species in tumour angiogenesis
  • Influenza virus induced complications in pregnancy
  • Investigating Host Inflammatory and Metabolic Mechanisms as Novel Targets Against Respiratory Infectious Diseases
  • Maternal and Fetal Complications During Influenza A Virus Infection
  • Investigating novel therapeutics for respiratory infectious diseases during pregnancy

Feature publications

Influenza A virus causes maternal and fetal pathology via innate and adaptive vascular inflammation in mice

Proceedings in the National Academy of Sciences (PNAS). 17, 24964 - 24973.

Liong, S.,oseghale, O.,to, E.,brassington, K.,erlich, J.,luong,r.,liong, F.,brooks, R.,martin, C.,o’toole, S.,vinh, a.,o'neill,l.,bozinovski, S.,vlahos, R.,papagianis, P.,o'leary, J.,brooks,d.,selemidis, S (2020).

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

Nature Communications, Jul 12;8(1):69

To E.e, Vlahos R, Luong R, Halls M.l, Reading P.c., King P.t, Chan C, Drummond G.r., Sobey C.g., Broughton B.r.s, Starkey M.r., Van Der Sluis R., Lewin S.r., Bozinovski S, Quach T, Porter C.j.h., Brooks D.a., O’leary, J.j and Selemidis S*. (2017).

Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets

Nature Reviews Drug Discovery. 10, 453- 471.

Drummond Gr, Selemidis S, Griendling K, Sobey Cg. (2011)

Key publications by year

  • Brassington K,..selemidis S, Vlahos R. Ebselen Reduces Cigarette Smoke-induced Endothelial Dysfunction In Mice. Br J Pharmacol. 2021 Apr;178(8):1805-1818. Doi: 10.1111/bph.15400. Epub 2021 Feb 27.pmid: 33523477 Free Pmc Article.
  • Ward Mp,.. Selemidis S, Et Al. Mol Cancer. 2021 Mar 31;20(1):59. Doi: 10.1186/s12943-021-01347-1.pmid: 33789677 Platelets, Immune Cells And The Coagulation Cascade; Friend Or Foe Of The Circulating Tumour Cell? Free Pmc Article. Review.
  • Chan Smh,..selemidis S, Et Al. Apocynin Prevents Cigarette Smoking-induced Loss Of Skeletal Muscle Mass And Function In Mice By Preserving Proteostaticsignalling. Br J Pharmacol. 2021 Apr 4. Doi: 10.1111/bph.15482. Online Ahead Ofprint.pmid: 33817783.
  • Vannitamby A,..selemidis S, Et Al. Aspirin-triggered Resolvin D1 Reduces Proliferation And The Neutrophil To Lymphocyte Ratio In A Mutant Kras-driven Lung Adenocarcinoma Model. Cancers (Basel). 2021 Jun 28;13(13):3224.doi:10.3390/cancers13133224.pmid: 34203378
  • To E.e, O’leary J.j O’neill Laj, Vlahos R, Bozinovski S, Porter C.j.h, Brooks R.d, Brooks D.a and Selemidis S*. (2020) Spatial Properties of Reactive Oxygen Species Govern Pathogen-specific Immune System Responses. Antioxidants and Redox Signalling. 1;32(13):982-992.
  • To E.e, Erlich J, Liong F, Luong, R, Liong S, Bozinovski S, O’leary J.j, Brooks D.a Vlahos R, and Selemidis S*. (2020). Mitochondrial Reactive Oxygen Species Contribute to Pathological Inflammation During Influenza a Virus Infection in Mice. Antioxidants and Redox Signaling. 1;32(13):929-942.
  • Anthony D, Papanicolao a, Wang H, Seow Hj, to Ee, Yatmaz S, Anderson Gp, Wijburg O, Selemdis S, Vlahos R, Bozinovski S. (2020). Excessive Ros Inhibits Il-17a+γδ T Cells and Innate Cellular Responses to Bacterial Lung Infection. Antioxidants and Redox Signaling. 1;32(13):943-956.
  • Jonathan R. Erlich, *eunice E. To, Stella Liong, Ross Vlahos, John J. O’leary, Doug a. Brooks and Selemidis S. 2020 Targeting Evolutionary Conserved Oxidative Stress and Immunometabolic Pathways for the Treatment of Respiratory Infectious Diseases. Antioxidants and Redox Signaling. 1;32(13):993-1013.
  • Chan Smh, Cerni C, Passey S, Seow Hj, Bernardo I, Van Der Poel C, Dobric a, Brassington K, Selemidis S, Bozinovski S, Vlahos R. 2020. Cigarette Smoking Exacerbates Skeletal Muscle Injury Without Compromising Its Regenerative Capacity. Am J Respir Cell Mol Biol. Feb;62(2):217-230. Doi: 10.1165/rcmb.2019-0106oc.pmid: 31461300.
  • Sorvina a, Shandala T, Wang S, Sharkey Dj, Parkinson-lawrence E, Selemidis S, Brooks Da. Cdki-73 Is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion. Cells. 2020 Feb 5;9(2):372. Doi: 10.3390/cells9020372.v
  • Liong S., Oseghale O, to E.e, Brassington K, Erlich J.r, Luong R, Liong F, Brooks R, Martin C, O’toole S, Vinh a, O’neill Laj, Bozinovski S, Vlahos R, Papagianis Pc, O’leary Jj, Brooks Da and Selemidis S. 2020 Influenza a Virus Causes Maternal and Foetal Pathology via Innate and Adaptive Vascular Inflammation. Proceedings of the National Academy of Sciences Usa, Accepted 6th August.
  • Bates M,..selemidis S, O'toole S, O'leary Jj. 2020. The Role of the Mad2-tlr4-myd88 Axis in Paclitaxel Resistance in Ovarian Cancer. Plos One. 2020 Dec 28;15(12):e0243715. Doi: 10.1371/journal.pone.0243715. 2020.pmid: 33370338 Free Pmc Article.
  • Selemidis S. (2019). Targeting Reactive Oxygen Species for Respiratory Infection: Fact or Fancy? Respirology. Jan;24(1):15-16. Doi: 10.1111/resp.13417.
  • To E.e, Erlich J, Liong F, Luong, R, Liong S, Bozinovski S, Seow H-j, O’leary J.j, Brooks D.a Vlahos R, and Selemidis S*. (2019). Intranasal and Epicutaneous Administration of Toll-like Receptor-7 (Tlr7) Agonists Provides Protection Against Influenza a Virus-induced Morbidity in Mice. Scientific Reports.
  • To Ee, Luong R, Diao J, O' Leary Jj, Brooks Da, Vlahos R, Selemidis S*. (2019). Novel Endosomal Nox2 Oxidase Inhibitor Ameliorates Pandemic Influenza a Virus-induced Lung Inflammation in Mice. Respirology. 2019 Mar 18. Doi: 10.1111/resp.13524.
  • Brassington K, Selemidis S, Bozinovski S, Vlahos R. (2019). New Frontiers in the Treatment of Comorbid Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. Clin Sci (Lond). 2019 Apr 12;133(7):885-904. Doi: 10.1042/cs20180316. Print 2019 Apr 15.
  • Chan Smh, Selemidis S, Bozinovski S, Vlahos R. (2019). Pathobiological Mechanisms Underlying Metabolic Syndrome (Mets) in Chronic Obstructive Pulmonary Disease (Copd): Clinical Significance and Therapeutic Strategies. Pharmacol Ther. 2019 Jun;198:160-188. Doi: 10.1016/j.pharmthera.2019.02.013. Epub 2019 Feb 26.
  • Ian R D Johnson, Alexandra Sorvina, Jessica M Logan, Courtney R Moore , Jessica K Heatlie, Emma J Parrkinson-lawrence, Stavros Selemidis, John J O’leary, Lisa M Butler and Douglas a Brooks a. 2019, Paradigm in Immunochemistry, Revealed by Monoclonal Antibodies to Spatially Distinct Epitopes on Syntenin-1. Int. J. Mol. Sci. 2019, 20(23), 6035; Https://doi.org/10.3390/ijms20236035.
  • Evans M.a., Lim R., Kim H.a., Chu H.x., Gardiner-mann C.v., Taylor K.w., Chan C.t., Brait V.h., Lee S, Dinh Q.n., Vinh a, Phan T.g., Srikanth V.k., Ma H., Arumugam T.v., Fann D.y., Poh L., Hunt C.p.j., Pouton C.w., Haynes J.m., Selemidis S., Kwan W., Teo L., Bourne J.a., Neumann S., Young S., Gowing. E.k, Drummond G.r., Clarkson a.n., Wallace E.m., Sobey C.g., Broughton B.r.s. (2018). Acute or Delayed Systemic Administration of Human Amnion Epithelial Cells Improves Outcomes in Experimental Stroke. Stroke. 49(3):700-709. Doi: 10.1161/strokeaha.117.019136.
  • Wang H, Anthony D, Selemidis S, Vlahos R, Bozinovski S. (2018). Resolving Viral-induced Secondary Bacterial Infection in Copd: a Concise Review. Front Immunol. Oct 16;9:2345. Doi: 10.3389/fimmu.2018.02345.
  • Harrison, Ip, Vinh, a. Johnson, Ird, Luong, R, Drummond, Gr, Sobey, Cg, Tiganis, T, Williams, Ed, O’ Leary, Jj, Brooks Da and Selemidis S*. (2018). Nox2 Oxidase Expressed in Endosomes Promotes Cell Proliferation and Prostate Tumour Development. Oct 23;9(83):35378-35393,oncotarget.
  • To E.e, .. Selemidis S*. (2017). Endosomal Nox2 Oxidase Exacerbates Virus Pathogenicity and Is a Target for Antiviral Therapy. Nature Communications, Jul 12;8(1):69. Doi: 10.1038/s41467-017-00057-x. I Am Sole Senior and Corresponding Author.
  • King P.t.,…selemidis S, Et Al (2017) Deoxyribonuclease 1 Reduces Pathogenic Effects of Cigarette Smoke Exposure in the Lung. Scientific Reports, Sep 21;7(1):12128. Doi: 10.1038/s41598-017-12474-5.
  • Oostwoud Lc, ..selemidis S, Et Al (2016). Apocynin and Ebselen Reduce Influenza a Virus-induced Lung Inflammation in Cigarette Smoke-exposed Mice. Scientific Reports. Feb 15;6:20983. Doi: 10.1038/srep20983.
  • Akhter M.h, ..selemidis S, Et Al (2016). A Single-chain Derivative of Therelaxin Hormone Is a Functionally Selective Agonist of the G Protein-coupled Receptor, Rxfp1. Chemical Science. Doi: 10.1039/c5sc04754d. 
Web

Feature projects

Targeting endosomal NOX2 oxidase in viral disease

Funding - National Health and Medical Research Council (NHMRC) $791,796

Selemidis S. Vlahos, R, Brooks DA, Porter C, O'Leary JJ.

2017 - 2020

Endosomal reactive oxygen species intumour angiogenesis

Funding - National Health and Medical Research Council (NHMRC) $633,739.00

Selemidis S, Brooks, DA, O'Leary JJ

2017 - 2021

Influenza A viral infection and pregnancy complications

Funding - National Health and Medical Research Council (NHMRC) $1,346,858.00

2016 - 2021

Key projects by year

  • 2021-2024. NHMRC Project Grant. CIA Selemidis, Liong. Influenza A viral infection and pregnancy complications.
  • 2020- ongoing. Lead Selemidis S, Brooks DA and O’Leary JJ. Advent ofViraLoK Therapeutics. Antiviral therapeutic development.
  • 2019-2020. Brooks DA,…Selemidis S, et al. Companion diagnostics and therapeutics for cancer. Envision Sciences Pty. Ltd. Translational Research Grant.
  • 2018-2019. Brooks DA,...Selemidis S, et al. Developing biomarkers and therapeutics for primary and metastatic lung cancer. UniSA RTIS.
  • 2017-2018. Brooks DA,.. Selemidis S et al. Prostate cancer diagnosis and prognosis. Envision Sciences Pty. Ltd. Translational Research Grant.
  • 2017-2019. NHMRC Project Grant. CIA Selemidis, Vlahos, Porter, Brooks and O’Leary. Targeting endosomal NOX2 oxidase in viral disease.
  • 2017-2019. NHMRC Project Grant. CIA Selemidis, Brooks and O’Leary. Endosomal reactive oxygen species in tumour angiogenesis.
  • 2016. Monash Strategic Grants Scheme. CIA Selemidis, Porter, Vlahos and Brooks. Application SGS16-0438. "Oxidative stress and viral disease"
  • 2012-2016. Australian Research Council Future Fellowship. (FT 120100876) CIA Selemidis S. Understanding the biology of reactive oxygen species.
  • 2010-2011. National Heart Foundation of Australia G 08M 3720. CIA SelemidisS, CIB Sobey CG, and Drummond GR.
  • 2010-2012. Cancer Council of Victoria. CIA Selemidis S, CIB, Williams E and CIC Drummond GR. Novel pharmacological strategies for tumour angiogenesis.
Web

Awards

Picture of a vertical rectangular award document. The document header says "Certificate of Recognition". Underneath the header it says "STEM College Research Excellence Award" and "Has been awarded to Associate Professor Stavros Selemidis".

Fukuchi Award 2019

Award date: 20th August 2019

Asian Pacific Society of Respirology for the most outstanding research paper published in Respirology. Title: Novel endosomal NOX2 oxidase inhibitor ameliorates pandemic influenza A virus‐induced lung inflammation in mice. Respirology, 24, 1011-1017.

Recipients: Stavros Selemidis


RMIT Award for Research Excellence- Team Award Chronic Infectious and Inflammatory Diseases

Award date: RMIT Research Awards 2018

Recipients: Prof Melissa Churchill, Prof Steven Bozinovski, Assoc Prof Janine Danks, Prof Paul Gorry, Assoc Prof Anthony Jaworowski, Dr Jonathan McQualter, Assoc Prof Samantha Richardson, Assoc Prof Stavros Selemidis, Prof Ross Vlahos

Winner of the Best Scientific Presentation at the Cell Biology Section of TSANZ conference in Adelaide

Award date: 2014

Recipients: Stavros Selemidis

STEM College Research Excellence Award as part of the 2021 STEM College Staff Awards

Award date: 2021

Recipients: Stavros Selemidis

Key awards by year

  • 2021 STEM College Research Excellence Award as part of the 2021 STEM College Staff Awards.
  • 2019 Winner of the Fukuchi Award in 2019, awarded by the Asian Pacific Society of Respirology for the most outstanding research paper published in Respirology. Title: Novel endosomal NOX2 oxidase inhibitor ameliorates pandemic influenza A virus‐induced lung inflammation in mice. Respirology, 24, 1011-1017.
  • 2018 RMIT Research Awards: RMIT Award for Research Excellence- Team Award Chronic Infectious and Inflammatory Diseases.
  • 2014 Winner of the Best Scientific Presentation at the Cell Biology Section of TSANZ conference in Adelaide, April, 2014.
  • 2012 Winner of the Best Scientific Presentation at the Cell Biology Section of TSANZ conference in Canberra, April, 2012.
  • 2005 Denis Wade Johnson & Johnson Young Investigator award for the Proceedings of the Australian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) 2005, Melbourne Australia.
  • 2000 Winner of the Best Scientific Presentation at the 3rd workshop on Endothelium-dependent hyperpolarising factor (EDHF) in Paris, June, 2000.
Web

Grants

National competitive grants – external sources

  • 2003-2006 NHMRC Peter Doherty Research Fellowship (ID 232324). CIASelemidis. $254000.
  • 2005. Monash Start-up Fund-linked with Peter Doherty Fellowship. Amount: $50000
  • 2006 Australian Research Council (ARC) Linkage Infrastructure Equipment Fund (LIEF; LE0775660). Schmidt HHHW, CIB Selemidis S, et al. A National Biomedical EPR and Molecular Imaging Centre. Amount: ARC $500,000; Monash/Melbourne and University Queensland $788,500.
  • 2010-2011. National Heart Foundation of Australia G 08M 3720. CIA SelemidisS, CIB Sobey CG, and Drummond GR. Amount: $129,000
  • 2010-2012. Cancer Council of Victoria. CIA Selemidis S, CIB, Williams E and CIC Drummond GR. Novel pharmacological strategies for tumour angiogenesis. Amount: $300,000.
  • 2012-2016. Australian Research Council Future Fellowship. (FT 120100876) CIA Selemidis S. Understanding the biology of reactive oxygen species. Amount: $707,000
  • 2012-2016. Monash Start-up Fund-linked with ARC Future Fellowship.Selemidis S $70,000.
  • 2016. Monash Strategic Grants Scheme. CIA Selemidis, Porter, Vlahos and Brooks. Application SGS16-0438. "Oxidative stress and viral disease"; Amount: $33,000.
  • 2017-2019. NHMRC Project Grant. CIA Selemidis, Vlahos, Porter, Brooks and O’Leary (GNT 1128276). Targeting endosomal NOX2 oxidase in viral disease. Amount: $791,796.
  • 2017-2019. NHMRC Project Grant. CIA Selemidis, Brooks and O’Leary. (GNT 1122506). Endosomal reactive oxygen species in tumour angiogenesis. Amount: $633,739.
  • 2021-2024. NHMRC Project Grant. CIA Selemidis, Liong. (GNT 2002948). Influenza A viral infection and pregnancy complications. Amount: $1,346,858

Industry funding – external sources

  • 2017-2018. Brooks DA,.. Selemidis S et al. Prostate cancer diagnosis and prognosis. Envision Sciences Pty. Ltd. Translational Research Grant. Amount: $2,930,165.
  • 2018-2019. Brooks DA,...Selemidis S, et al. Developing biomarkers and therapeutics for primary and metastatic lung cancer. UniSA RTIS – Seed funding. Amount $40,000.
  • 2019-2020. Brooks DA,…Selemidis S, et al. Companion diagnostics and therapeutics for cancer. Envision Sciences Pty. Ltd. Translational Research Grant. Amount $3,626,666.
  • 2018-2019. Orgeig S,.. Selemidis S et al. UniSA Strategic Funding Grant. Amount $20,000.
  • 2019-2022. Brooks DA,. Selemidis S, et al. UniSA Support Grant for Cancer Research Translation Programme. UniSA Division of Health Sciences ($125,000/yr) and UniSA Innovation Services ($283,000/yr). Amount $1,632,000 ($408,000/yr)
  • 2020-2021. Lead Selemidis S, Brooks DA and O’Leary JJ. Advent of ViraLoKTherapeutics. Philanthropy funding. Amount $1 043 000.
Web

Public and media engagements

Media Engagemen Due To The Original Article In Nature Communications

Altmetric Score: 184

(To E.E, Vlahos R, Luong R, Halls M.L, Reading P.C., King P.T, Chan C, Drummond G.R., Sobey C.G., Broughton B.R.S, Starkey M.R., Van Der Sluis R., Lewin S.R., Bozinovski S, Quach T, Porter C.J.H., Brooks D.A., O’leary, J.J And Selemidis S*. (2017). Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. Nature Communications, Jul 12;8(1):69. Doi: 10.1038/s41467-017-00057-x.) 

  • Live ABC news 7.30pm 12th July, 2017. 
  • News story interview for Channel 7, on the 13th of July, 2017 
  • News story interview for Channel 9 on the 13th of July, 2017 
  • News story interview for Channel 10 on the 13th of July, 2017. 
  • Live radio interview on ABC Melbourne Drive on the 13th of July, 2017 
  • Live radio interview on ABC Sydney on the 13th of July, 2017 
  • Live radio interview on ABC Adelaide on the 13th of July, 2017 
  • Live radio interview on 6PR Perth on the 13th of July, 2017. 
  • Live radio interview on ABC Perth Drive on the 13th of July, 2017. 
  • Radio interview on SBS Greek Radio

Media Engagement Due To Original Article In Pnas In 2020

Altmetric Score: 170

Liong, S.,Oseghale, O.,To, E.,Brassington, K.,Erlich, J.,Luong,R.,Liong, F.,Brooks, R.,Martin, C.,O’toole, S.,Vinh, A.,O'neill,L.,Bozinovski, S.,Vlahos, R.,Papagianis, P.,O'leary, J.,Brooks,D.,Selemidis, S (2020). Influenza A virus causes maternal and fetal pathology via innate and adaptive vascular inflammation in mice In: Proceedings in the National Academy of Sciences (PNAS). 17, 24964 - 24973. 

The study was featured in over 200 online and broadcast stories in mainstream, science and medical media in Australia and globally. The combined audience for the online news sites where the research featured is over 382 million. Advertising value estimated at over $AUD3.5 million.

Web
aboriginal flag
torres strait flag

Acknowledgement of country

RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business - Artwork 'Luwaytini' by Mark Cleaver, Palawa.

aboriginal flag
torres strait flag

Acknowledgement of country

RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business.